DrugPatentWatch Database Preview

Details for Patent: 8,778,997

« Back to Dashboard

Which drugs does patent 8,778,997 protect, and when does it expire?

Patent 8,778,997 protects RAPIVAB and is included in one NDA.

This patent has thirty-three patent family members in fourteen countries.

Summary for Patent: 8,778,997

Title:	Antiviral treatments
Abstract:	The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
Inventor(s):	Babu; Yarlagadda Sudhakara (Birmingham, AL), Chand; Pooran (Birmingham, AL), Bantia; Shanta (Birmingham, AL), Arnold; Shane (Hoover, AL), Kilpatrick; John Michael (Helena, AL)
Assignee:	BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:	13/103,562
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,778,997

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

International Family Members for US Patent 8,778,997

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006341592
Australia	2007215156
Australia	2013216632
Australia	2016262644